The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
POLARIX: How does MYC and BCL2 expression impact outcomes post frontline treatment with PV in DLBCL?
Featured:
Gilles SallesDuring the EHA 2022 Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, POLARIX trial: How does MYC and BCL2 expression impact outcomes post frontline treatment with polatuzumab vedotin (PV) in diffuse large B-cell lymphoma (DLBCL).
POLARIX: How does MYC and BCL2 expression impact outcomes post frontline treatment with PV in DLBCL?
Salles discusses the activity of the combination polatuzumab vedotin + rituximab-CHOP in patients with DLBCL, and some chromosomal abnormalities. Salles outlines the consequences of BCL2 overexpression on treatment outcomes, and the improvement that this combination has shown for this patient group.